Publications by authors named "U Koehl"
Article Synopsis
- The introduction highlights the rapid growth of point-of-care (POC) manufacturing for chimeric antigen receptor (CAR) modified T cells, particularly focusing on anti-CD20 CAR T cells for melanoma patients in a phase I clinical trial.
- The methods used involved producing CD20 CAR T cells using a second-generation lentiviral vector on the CliniMACS Prodigy® platform, demonstrating high purity and functionality across two production sites.
- Results confirmed a sufficient expansion and activation capability of the CAR T cells, revealing interindividual differences in their response, thereby supporting the effectiveness of the CliniMACS Prodigy® for decentralized CAR T cell manufacturing.
Chimeric antigen receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer. Currently, there are six approved CAR T cell products available on the market that target different malignancies of the B cell lineage. However, to overcome the limitations of CAR T cell therapies, other immune cells are being investigated for CAR-based cell therapies.
View Article and Find Full Text PDFArticle Synopsis
- Primary mediastinal germ-cell tumors (PMGCTs) represent a small percentage of all germ-cell tumors, notably having a poorer prognosis compared to gonadal tumors, with low overall survival rates especially in cases with metastases.
- A retrospective study assessed the effectiveness of high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for treating 69 adult male patients with primary mediastinal non-seminoma germ cell tumors (PMNSGCT), primarily using carboplatin/etoposide.
- Results showed that upfront HDC significantly improved progression-free survival and overall survival rates, with a 2-year overall survival rate of 43.3% for the cohort, while identifying predictors for better
For the monitoring of chimeric antigen receptor (CAR) T-cell therapies, antigen-based CAR detection methods are usually applied. However, for each target-antigen, a separate detection system is required. Furthermore, when monitored CAR T-cells in the blood of patients treated with bispecific antibodies or T-cell engagers (bsAbs/BiTEs) recognize the same antigen, these methods produce false-positive results in clinical diagnostics.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic cell therapies, particularly those using NK cells and macrophages, face challenges in genetic modification due to inefficiencies in current viral vector techniques.
- The study introduces a new lentiviral pseudotype using the Koala Retrovirus envelope, which efficiently transduces freshly isolated human NK cells and monocytes with up to 80% gene expression without compromising cell functionality.
- This innovation streamlines the production of cell-based therapeutics, making it quicker and less resource-intensive, which could lead to faster patient access to effective cancer treatments.